Evergreen Therapeutics is a Maryland-based innovative biopharmaceutical company established in 2019 with artificial intelligence (AI) as one of its core technologies. we have a cross-border integration team that brings together top talents in clinical medicine, computing science, chemistry, pharmacology, and FDA regulations in product registration, focusing on the discovery of innovative drugs in the field of ophthalmology, vascular and autoimmunity, as well as the efficient clinical development and commercialization on a global scale.
We always adhere to the principles of true clinical differentiation, high efficiency, and development to satisfy the needs of the major global markets. Evergreen uses the unique AI computing platform for the entire drug development life cycle from the synthesis and optimization of novel molecules, pharmacological and toxicological prediction to indication selection and optimization in clinical trial designs. 3 pipelines have entered clinical development stages of Phase I-II.
Evergreen has a strong pharmaceutical and artificial intelligence technology team, bringing together top talents in clinical medicine, computing science, chemistry, pharmacology/toxicology, and FDA registration regulations, and has a unique AI research and development platform, comprehensive capabilities and professional experience in pharmaceutical regulations and clinical trial design / management. On the one hand, the company actively engages in the research and development of its own drug pipeline, on the other hand, it provides innovative drug development services and cooperation for pharmaceutical companies with artificial intelligence research and development needs, helps customers and partners to solve the difficulties from drug discovery to clinical process in a "one-stop" manner, and provides flexible and efficient research and development solutions.
